Back to medications
Medication monograph

lisocabtagene maraleucel

Chimeric Antigen Receptor T-cell (CAR-T) TherapyImmunotherapy AgentsCD19-Directed Genetically Modified Autologous T-cell Immunotherapies

Clinical reference

Product monograph

BREYANZI- lisocabtagene maraleucel kit

Brands & formulations

Family members

BREYANZI

Marketed
120000000 CELLSINTRAVENOUSSUSPENSION[ "lisocabtagene maraleucel" ]
Product monograph

Classification

Chemical class
Chimeric Antigen Receptor T-cell (CAR-T) Therapy
Clinical class
Immunotherapy Agents
Banks class
CD19-Directed Genetically Modified Autologous T-cell Immunotherapies